Sophiris Bio (SPHS) Sees Large Volume Increase
Shares of Sophiris Bio Inc (NASDAQ:SPHS) saw strong trading volume on Monday . 1,004,201 shares traded hands during trading, an increase of 258% from the previous session’s volume of 280,653 shares.The stock last traded at $2.05 and had previously closed at $1.89.
A number of brokerages have weighed in on SPHS. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a report on Friday, September 15th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a “buy” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Sophiris Bio has a consensus rating of “Buy” and an average target price of $6.25.
The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Stock Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related stocks with our FREE daily email newsletter.